Tianjin Pharmaceutical Da Ren Tang Group's strong financials hint at potential for long-term value increase despite recent stock price drop. Analysts predict continued earnings expansion due to the company's high ROE, net income growth, and efficient reinvestment.
Tianjin Pharmaceutical Da Ren Tang Group's low P/E ratio may reflect the market's pessimistic view of its future earnings growth. The weak share price, leading to a lower P/E ratio, suggests that unless the company's earnings outlook improves, the share price may remain suppressed.
Tianjin Pharmaceutical Da Ren Tang Group's commendable performance is due to reinvestment and high return rate, driving significant earnings growth, with predictions of accelerated earnings.
$TJ DaRenTang USD (T14.SG)$ TJ exceeded its tp of USD1.91. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited produces and sells traditional Chinese medicine, western medicine, health products, and healthcare instruments. The Company also manufactures gene-related biopharmaceutical products. Tianjin Pharmaceutical markets its products under the Great Wall, Cypress, and Health brand names. The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese me...
Tianjin Pharmaceutical Da Ren Tang Group Corporation Stock Forum
New variant of COVID-19 is soaring in Singapore. Gryphon or XBB is a fast-spreading new subvariant that is part of a 'new class' of Omicron.
MSN
$Tianjin Pharmaceutical Da Ren Tang Group Corporation (600329.SH)$ $Acesian Partners (5FW.SG)$ $Parkson Retail (O9E.SG)$
TJ exceeded its tp of USD1.91.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited produces and sells traditional Chinese medicine, western medicine, health products, and healthcare instruments. The Company also manufactures gene-related biopharmaceutical products. Tianjin Pharmaceutical markets its products under the Great Wall, Cypress, and Health brand names. The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese me...
huge difference in Shanghai and Singapore for this stock.
No comment yet